Pharma's Market
SPECIAL REPORT
MOST SHARED
- UK's Cameron Calls for Truce on Bonuses
- Greek Debt Saga Back on Center Stage for Markets
- For China's Xi, Near-Summit Treatment and 'Iowa Nice'
- Greece Warns Bailout Rebels of Unknown, Dangerous Path
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- How Rescuing Greece Could Destroy the World
- Greek Police Union Wants to Arrest EU, IMF Officials
- Warren Buffett's 5-Minute Plan to Fix the Deficit
- Dividend Payout Could Hit Record Amount This Year
- In Search of America's ‘Hottest Forecasters’
- Dow vs. S&P 500: Which is a Better Investment?
- Mick Fleetwood on the MP3 ‘Dumbing Down’ of Music
- Avis on the Road to Strong Growth: Analyst
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- Maine Caucuses a Chance to Right the Romney Ship
- Greek Debt Saga Back on Center Stage for Markets
- Greece Now Struggles to Overcome Mistrust
- Obama Budget Bets Other Concerns Will Trump the Deficit
- China President-in-Waiting to Sample Slices of America
- MF Global Trustee Sees Shortfall of $1.6 Billion
- Iran to Announce 'Very Important' Nuclear Progress
- Traveling Light in a Time of Digital Thievery
- UK Police Arrest Five at Murdoch's Sun Newspaper
RSS FEED
Merck's Gardasil For Boys: How Will Those Ads Play?
Text Size 
Reporter
 |
CNBC.com photo composite Gardasil |
] has been testing its cervical cancer vaccine Gardasil on young men (16-23 years old). The company says major data on those clinical trials are expected next year and could help Merck win FDA approval of the shots for males as well as females. The first-of-its-kind product has already sparked a sociopolitical controversy with its recommended use for young women. Imagine the brouhaha if or when Merck starts selling it for young men.That effort is getting a shot in the arm (bad, cliche pun intended) today from doctors at the prestigious M.D. Anderson Cancer Center who write a review in the medical journal "Cancer" about HPV-16 (one of the strains of the human papillomavirus that can lead to cancer) being tied to oropharyngeal, or a type of oral cancer.
The researchers conclude, "To hasten the reduction of HPV-16 in the population, widespread vaccination of adolescent and young adult males should also be considered. Although the cervical cancer...prevention policy of the HPV-16/18 (another leading cancer-causing strain) vaccination of young women and adolescent females are commended, we fear that vaccination programs limited to females will only delay the potential benefit in prevention of HPV-16/18-associated oropgaryngeal cancers, which typically occur in men. We encourage the rapid study of the efficacy and safety of these vaccines in males and, if successful, the recommendation of vaccination in young adult and adolescent males." One of the doctors who wrote the article has been a consultant for GSK.
Gardasil is well on its way to becoming a major blockbuster for Merck. GlaxoSmithKline [GSK
Loading...
()
] is awaiting FDA approval (for females) of a similar vaccine called Cervarix.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
